Levonorgestrel-releasing intrauterine system alone as primary treatment in young women with early endometrial cancer: case report.
Young women with polycystic ovary syndrome (PCOS) are at increased risk of endometrial adenocarcinoma (EAC) through chronic unopposed estrogen production. We describe the first case, to our knowledge, of grade 1 endometrioid EAC arising in the context of complex atypical endometrial hyperplasia in a 26-year-old woman with thrombophilia and PCOS who wished to retain fertility potential and was treated using a levonorgestrel-releasing intrauterine system alone. At first follow-up biopsy, a single focus of complex hyperplasia without atypia was documented. All specimens sampled during subsequent follow-up demonstrated inactive endometrium with pseudodecidual changes, and no ultrasonographic or magnetic resonance (MR) images exhibiting myometrial invasion or endoabdominal spread were observed. This successful outcome suggests that insertion of a levonorgestrel-releasing intrauterine system is a treatment option in selected young women with early-stage EAC who are not candidates for systemic therapy and who wish to maintain fertility potential. Close histologic follow-up is required, and immediate surgery is mandatory if endometrial cancer persists.
Fambrini
Massimiliano
M
Department of Gynecology, Perinatology, and Human Reproduction, University of Florence, Florence, Italy. maxfambrini@libero.it
Bargelli
Gianni
G
Peruzzi
Elena
E
Buccoliero
Anna Maria
AM
Pieralli
Annalisa
A
Andersson
Karin L
KL
Scarselli
Gianfranco
G
Gallorini
Marcella
M
Zolfanelli
Federica
F
Marchionni
Mauro
M
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000453:epidemiology; D000328:Adult; D015897:Comorbidity; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D007434:Intrauterine Devices; D016912:Levonorgestrel / Q000008:administration & dosage*; D011085:Polycystic Ovary Syndrome / Q000453:epidemiology
D003271:Contraceptive Agents, Female; D016912:Levonorgestrel